Sofpironium Bromide: First Approval

<p><b>Declarations</b></p> <p> </p> <p><i>Funding </i>The preparation of this review was not supported by any external funding.</p> <p> </p> <p><i>Authorship and Conflict of interest</i><i> </i>Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p> </p> <p><i>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</i><i> </i>Not applicable</p> <p> </p> <p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a><b></b></p><p><br></p> <p> </p> <p><b>Abstract</b></p> <p> </p> <p></p><p>Sofpironium bromide (ECCLOCK^®) gel is a topical anticholinergic agent developed by Bodor Laboratories and licenced to Brickell Biotech for the treatment of hyperhidrosis. The drug is designed to reduce sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. In September 2020, sofpironium bromide gel 5% received its first approval in Japan for the treatment of primary axillary hyperhidrosis (PAH). Clinical studies are currently ongoing in the USA to assess the safety and efficacy of sofpironium bromide gel 15% in PAH. This article summarizes the milestones in the development of sofpironium bromide gel leading to this first approval for the treatment of PAH. </p> <p> </p> <p>© Springer Nature Switzerland AG 2020</p>